HOME >> MEDICINE >> NEWS
Combination vaccine produces lower immune response than vaccines administered separately

A combination vaccine developed to reduce the number of vaccines infants receive appears to provide less immunity than the vaccines administered individually, according to a study in the April 13 issue of JAMA.

The development of immunogenic vaccines against major diseases of childhood has dramatically decreased the rates of invasive disease, according to background information in the article. Since the introduction of a monovalent serogroup C meningococcal glycoconjugate vaccine (MenC) into the United Kingdom routine immunization schedule in November 1999, group C meningococcal disease has decreased by 87 percent in the ages targeted for vaccination, with estimated vaccine efficacy of 90 percent. Within 2 years of the introduction of a 7-valent pneumococcal glycoconjugate vaccine into the recommended infant schedule in the United States, there was a 69 percent reduction in culture-positive invasive pneumococcal disease in children younger than 2 years.

The advent of these efficacious and safe vaccines has increased pressure on crowded infant immunization schedules. Infants in the United States receive up to 20 separate vaccine injections over 5 immunization encounters at ages 2, 4, 6, 12, and 18 months to protect against disease due to hepatitis B, diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, varicella, H influenzae type b, and pneumococcus. The inclusion of MenC would add a further 3 to 4 doses to the U.S. regimen. The development of combination vaccines has become a priority. The combining of pneumococcal and meningococcal conjugate vaccines has the potential to spare U.S. infants up to 4 extra injections by age 18 months and to decrease parental and clinician concerns about the number of vaccinations in early childhood.

Jim P. Buttery, F.R.A.C.P., formerly of the University of Oxford, Churchill Hospital, Headington, Oxford, U.K., and colleagues conducted a study to determine the immunogenicity and safety of a combinati
'"/>

Contact: Jim P. Buttery, F.R.A.C.P.
jim.buttery@rch.org.au
JAMA and Archives Journals
12-Apr-2005


Page: 1 2

Related medicine news :

1. Combination treatment stymies breast cancer growth
2. Combination therapy spares some head and neck patients from surgery
3. Combination of personality traits increases risk for heart disease
4. Combination therapy may improve survival for pancreatic cancer
5. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
6. Combination of three new, high-powered MRI systems at PENN is a first in the US
7. Dynamic duo: Combination therapy reverses type 1 diabetes
8. Combination of interventions can substantially reduce incidence of malaria in people with HIV
9. Combination therapy improves AIDS-related lymphoma outcome
10. Combination treatment for brain cancer not detrimental to patients quality of life
11. Combination microbicides protect monkeys against HIV-like virus

Post Your Comments:
(Date:9/1/2015)... ... ... For many men, the first thing they notice when they go to button their white ... fitting shirt with a collar that doesn’t close against the skin, creating a sloppy look. ... all day because it’s uncomfortable. Now men in suits will be able to do ...
(Date:9/1/2015)... ... September 01, 2015 , ... Earth Brands, ( ... fall collection. Every customer who buys an Earth Brand shoe will be given ... with Trees for the Future, a nonprofit dedicated to planting more trees. Earth ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty ... “The Beauty Behind the Fashion” on Thursday, Oct. 1, at the La Valencia ... the spotlight on the collaboration between fashion and professional hair, makeup and nail design. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... to efficiently cure and prevent different malignancies. Some options for cancer treatment ... properties due to which distinctive approach is necessary for effective treatment. Several ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
Breaking Medicine News(10 mins):Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2
(Date:9/1/2015)... OAKS, Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) ... (STudy evaluating effect of RomosozUmab Compared with Teriparatide ... for fracture pReviously treated with bisphosphonatE therapy). The ... statistically significant difference in favor of romosozumab in ...
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... 1, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, is scheduled to present at ... Hyatt Regency Boston in Boston, Massachusetts ... Michael A. Mussallem , Edwards Lifesciences, chief executive officer, ... a company discussion with conference attendees at 10:10 a.m. ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
Cached News: